Model portefeuille
Rendement portefeulle
+12.035 %

Rendement AEX
+33.325 %


Startwaarde portefeuille € 74082.37

Startwaarde AEX
€ 245.94

Laatste update:

DSM reports results first nine months 2017

Alleen voor leden beschikbaar, wordt daarom gratis lid!

Algemeen advies 02/11/2017 07:05
Highlights YTD 2017
•Strong performance in Q3, contributing to very good first nine months
•Sales up 9% to €6,456m, with 8% organic growth
•Adjusted EBITDA up 15% to €1,086m, driven by both Nutrition and Materials
•ROCE up 170 bps to 12.3%
•Adjusted Net profit up 29% to €504m
•Total Net profit of €1,603m, including gain on Patheon disposal of €1,250m
•Outlook 2017 unchanged

Key figures and indicators
in € million
Jan - Sep 2017 Jan - Sep 2016 % change Vol. Price /mix FX other

Sales 6,456 5,905 9% 7% 1% 1% 0%
Nutrition 4,151 3,848 8% 6% 1% 1% 0%
Materials 2,132 1,874 14% 8% 5% 0% 1%
Adjusted EBITDA
(cont. ops)1 1,086 947 15%
Nutrition 786 693 13%
Materials 369 330 12%
EBITDA (cont. ops) 1,032 904
ROCE (%) 12.30% 10.60%

1) Adjusted EBITDA (and adjusted Net profit) are Alternative Performance Measures (APM’s) that reflect continuing operations.
See page 11 of PDF version for definition and reconciliation

CEO statement

Feike Sijbesma, CEO and Chairman of the DSM Managing Board, commented: “We are pleased to report another strong quarter, resulting in a very good performance during the first nine months. Nutrition and Materials once again delivered organic growth rates well above their respective markets, with particularly good volume growth.

These results demonstrate significantly improved operational and financial performance, well ahead of plan, with all businesses delivering on their ambitious growth initiatives, and we are firmly on track with our cost-reduction and efficiency improvement programs. Furthermore, we successfully divested our share in Patheon ahead of schedule.

DSM confirms its full year 2017 outlook, despite slightly less favorable currency developments. In addition, with all of these developments ahead of plan we are bringing forward our regular strategic review process for the period beyond 2018 and anticipate communicating the results before mid-year 2018, as announced at our September Investor Event.”

Outlook 2017 unchanged

DSM expects to deliver full-year 2017 results above the targets set out in its Strategy 2018, with an EBITDA growth for the year slightly up from high single-digit to double digit, and with a ROCE increase from double digit basis points to over 100 basis points.

Q3 Highlights 2017
•DSM reports another strong quarter in Q3
•Sales up 7% to €2,136m, with 10% organic growth
•Adjusted EBITDA up 13% to €365m
•Nutrition: 8% organic sales growth; Adjusted EBITDA up 12%
•Materials: 9% volume growth; Adjusted EBITDA up 8%

see more on

tijd 09.09
DSM EUR 73,56 -27ct vol. 76.000

Beperkte weergave !
Leden hebben toegang tot meer informatie! Omdat u nog geen lid bent of niet staat ingelogd, ziet u nu een beperktere pagina. Wordt daarom GRATIS Lid of login met uw wachtwoord

Copyrights © 2000 by all rights reserved
Niets mag zonder toestemming van de redactie worden gekopieerd, linken naar deze pagina is wel toegestaan.